Steven L. Cook, who serves as the Chief Financial Officer for Omada Health, Inc. (NASDAQ:OMDA), has formally reported the disposition of company equity valued at $325,394. The transaction, which took place on June 22, 2026, involved the sale of 17,950 shares of common stock. The weighted average price per share for this disposal was recorded at $18.1278. These sales were not executed as a single block but were instead carried out through multiple trades, with execution prices varying between $18.00 and $18.30 per share. The disposition was facilitated under a pre-arranged 10b5-1 trading plan. Mr. Cook initially adopted this specific trading plan on March 14, 2026, establishing a structured framework for these transactions.
Concurrent with the sale activity on the same day, Mr. Cook also engaged in the acquisition of 17,950 shares of Omada Health common stock. These acquisitions were executed through the exercise of stock options. The total value associated with these option exercises amounted to $140,112. The exercise prices for these shares ranged from $7.68 to $8.01 per share. A detailed breakdown of these acquisitions indicates that Mr. Cook purchased 6,839 shares at an exercise price of $8.01 per share. Additionally, he acquired 11,111 shares at an exercise price of $7.68 per share. These simultaneous acquisition and disposition activities represent a complex set of transactions within the digital health sector.
The disclosure of these transactions was formalized through an amended Form 4, designated as Form 4/A. This amended filing serves to restate an original filing that was initially submitted on June 24, 2026. The primary purpose of this amendment was to include exercise transactions that were inadvertently omitted from the initial report. The amendment clarifies that these option exercises were part of same-day exercise-and-sale transactions. It is noted that the corresponding sales from these transactions had been previously reported. The correction made in this amended filing adjusts the calculation of the amount of securities beneficially owned by Mr. Cook following the sales.
The stock options that were exercised in this transaction are subject to various vesting schedules, which dictate when the shares become fully owned by the executive. For the 6,839 shares, the vesting schedule dictates that 1/48th of the shares subject to the option vested on each monthly anniversary starting from February 1, 2024. Full vesting for this tranche of options was achieved on the fourth anniversary. For the remaining 11,111 shares, the vesting schedule indicates that vesting occurred on each monthly anniversary starting from February 1, 2025. Similar to the first tranche, full vesting for these shares also occurred on the fourth anniversary. These structured vesting periods are typical in executive compensation packages within the technology and healthcare sectors.
Following the completion of these transactions, Mr. Cook’s direct ownership position in Omada Health stands at 187,209 shares of common stock. In addition to his direct equity holdings, Mr. Cook retains control over remaining derivative securities. These derivative holdings include 43,161 stock options with an expiration date set for February 8, 2034. Furthermore, he holds an additional 22,222 stock options that are scheduled to expire on January 27, 2035. This portfolio of equity and derivatives provides insight into the executive's long-term alignment with the company's performance.
Omada Health, which holds a current market valuation of $1.37 billion, presents a specific valuation profile in the current market environment. The stock currently trades above its InvestingPro Fair Value metric. This pricing dynamic places the company on the Most Overvalued list according to current analysis. Despite this valuation metric, analyst sentiment remains focused on future financial trajectories. According to InvestingPro Tips, analysts predict that the company is expected to achieve profitability within the current year. This prediction stands in contrast to the company's recent financial losses, highlighting a divergence between current operational results and future expectations. For investors seeking deeper insights into these financial projections, Omada’s comprehensive Pro Research Report is available, which is one of over 1,400 such reports available for US equities.
In the broader context of the company's recent financial performance, Omada Health reported its financial results for the first quarter of 2026. This reporting period revealed a positive earnings surprise relative to market expectations. The company achieved an earnings per share (EPS) of -$0.05. This result surpassed the forecasted EPS of -$0.08, indicating a better-than-expected operational performance. In terms of top-line growth, the company recorded a revenue of $78 million. This revenue figure represents a significant 42% year-over-year growth, demonstrating strong expansion in the digital health sector.
Following the release of these financial results, institutional analyst sentiment was adjusted. Citizens, a financial services firm, raised its price target for Omada Health to $21. This adjustment was made from a previous price target of $18. The firm maintained a Market Outperform rating for the stock. This adjustment reflects a positive growth outlook for the company within the healthcare technology space. Analyst Constantine Davides from Citizens provided specific valuation context, highlighting that Omada Health recently traded at 2.5 times the firm’s 2026 revenue estimate. This multiple suggests that the market is pricing in significant future revenue growth.
Corporate governance developments also occurred recently for Omada Health. The company held its 2026 Annual Meeting of Stockholders. During this meeting, strategic board changes were implemented. Sean Duffy and Trevor Fetter were elected as Class I Directors. Both elected directors are scheduled to serve until the 2029 annual meeting. These governance changes, combined with the financial results and analyst upgrades, indicate a series of strategic and financial advancements for Omada Health. The company continues to navigate the complexities of the digital health market while attempting to transition toward sustained profitability.